Dyne Therapeutics, Inc. (NASDAQ:DYN – Get Free Report) Director Brian Posner acquired 2,500 shares of Dyne Therapeutics stock in a transaction on Friday, October 2nd. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $40,000.00. Following the acquisition, the director owned 27,000 shares in the company, valued at approximately $432,000. This represents a 10.20% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Dyne Therapeutics Trading Down 0.3%
Shares of NASDAQ DYN traded down $0.04 during midday trading on Tuesday, hitting $15.40. The stock had a trading volume of 4,091,193 shares, compared to its average volume of 2,276,174. The firm has a market cap of $2.88 billion, a P/E ratio of -4.62 and a beta of 1.12. Dyne Therapeutics, Inc. has a fifty-two week low of $12.77 and a fifty-two week high of $27.31. The company has a debt-to-equity ratio of 0.28, a current ratio of 12.02 and a quick ratio of 12.02. The company’s 50-day simple moving average is $22.31 and its 200 day simple moving average is $20.54.
Dyne Therapeutics (NASDAQ:DYN – Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.33). Research analysts anticipate that Dyne Therapeutics, Inc. will post -3.59 EPS for the current year.
Institutional Investors Weigh In On Dyne Therapeutics
Analyst Upgrades and Downgrades
Several brokerages have recently issued reports on DYN. Jefferies Financial Group reaffirmed a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a research note on Wednesday, September 30th. JPMorgan Chase & Co. lowered shares of Dyne Therapeutics from a “neutral” rating to an “underweight” rating and cut their price objective for the company from $17.00 to $10.00 in a report on Wednesday, September 9th. Royal Bank Of Canada reduced their price objective on shares of Dyne Therapeutics from $35.00 to $30.00 and set an “outperform” rating on the stock in a research note on Wednesday, September 9th. Wall Street Zen downgraded Dyne Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 1st. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $37.00 price objective on shares of Dyne Therapeutics in a research note on Tuesday, September 8th. Two research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Dyne Therapeutics has an average rating of “Moderate Buy” and an average price target of $33.07.
Read Our Latest Stock Analysis on Dyne Therapeutics
About Dyne Therapeutics
Dyne Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing genetic medicines for serious neuromuscular diseases. The company’s research is centered on its FORCE platform, which is designed to use targeted antibodies to deliver oligonucleotide-based therapies to skeletal muscle and other relevant tissues.
Dyne’s development programs include DYNE-101, an investigational therapy for myotonic dystrophy type 1, and DYNE-251, an investigational exon-skipping therapy for Duchenne muscular dystrophy in patients amenable to exon 51 skipping.
Featured Stories
- Five stocks we like better than Dyne Therapeutics
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for Dyne Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dyne Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
